Proportion of each human cell lineage engrafted in primary NOG mice
. | . | Bone marrow, % engrafted . | . | . | . | . | Spleen, % engrafted . | . | . | . | Thymus, % engrafted . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse . | Week* . | CD45 . | EGFP . | S . | M . | B . | CD45 . | EGFP . | T . | B . | CD45 . | EGFP . | T . | |||||||||
| 1 | 17 | 82.2 | 84.8 | 22.1 | 4.6 | ND | 81.8 | 65.3 | 2.1 | 88.6 | 97.8 | 83.0 | 82.6 | |||||||||
| 3 | 17 | 74.0 | 58.5 | 5.2 | 33.5 | 44.4 | 82.1 | 78.2 | 24.2 | 62.4 | 85.5 | 80.0 | 71.0 | |||||||||
| 4 | 16 | 88.9 | 75.4 | 8.5 | 17.5 | 64.4 | 75.6 | 77.9 | 1.6 | 87.9 | 95.0 | 52.9 | 23.4 | |||||||||
. | . | Bone marrow, % engrafted . | . | . | . | . | Spleen, % engrafted . | . | . | . | Thymus, % engrafted . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse . | Week* . | CD45 . | EGFP . | S . | M . | B . | CD45 . | EGFP . | T . | B . | CD45 . | EGFP . | T . | |||||||||
| 1 | 17 | 82.2 | 84.8 | 22.1 | 4.6 | ND | 81.8 | 65.3 | 2.1 | 88.6 | 97.8 | 83.0 | 82.6 | |||||||||
| 3 | 17 | 74.0 | 58.5 | 5.2 | 33.5 | 44.4 | 82.1 | 78.2 | 24.2 | 62.4 | 85.5 | 80.0 | 71.0 | |||||||||
| 4 | 16 | 88.9 | 75.4 | 8.5 | 17.5 | 64.4 | 75.6 | 77.9 | 1.6 | 87.9 | 95.0 | 52.9 | 23.4 | |||||||||
The total cellularity of BM and thymus in the primary recipient was 3.56 × 107 ± 0.53 × 107 and 1.39 × 105 ± 1.13 × 105, respectively. Each mouse listed in the table received a transplant of 10 × 103 CD34+CD38- cells.
S indicates CD34+ stem/progenitor cells; M, CD33+ myeloid lineage cells; B, CD19+ B-lymphoid lineage cells; T, CD3+ (spleen) or CD4/CD8 double-positive (thymus) T-lymphoid lineage cells; ND, not done.
Weeks after transplantation. Bone marrow cells, spleen cells, and thymocytes of NOG mice were stained with an anti—human CD45 mAb and analyzed. The proportion of EGFP-expressing cells within the CD45+ cells and cells positive for each lineage marker in the CD45+/EGFP+ was calculated.